Prognostic role of PET/MRI hybrid imaging in patients with pulmonary arterial hypertension. Issue 1 (10th June 2020)

• Record Type: Journal Article
• Authors: Kazimierczyk, Remigiusz; Szumowski, Piotr; Nekolla, Stephan G; Blaszczak, Piotr; Malek, Lukasz A; Milosz-Wieczorek, Barbara; Misko, Jolanta; Jurgilewicz, Dorota; Hladunski, Marcin; Knapp, Malgorzata; Sobkowicz, Bozena; Mysliwiec, Janusz; Grzywna, Ryszard; Musial, Wlodzimierz J; Kaminski, Karol A
• Is Part Of: Heart. Volume 107:Issue 1(2021)
• Page Start: 54
• Page End: 60
• Publication Date: 2020-06-10
• Subjects: positron emission tomographic (PET) imaging -- primary pulmonary hypertension -- cardiac magnetic resonance (CMR) imaging; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2020-316741
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: Right ventricular (RV) function is a major determinant of survival in patients with pulmonary arterial hypertension (PAH). Metabolic alterations may precede haemodynamic and clinical deterioration. Increased RV fluorodeoxyglucose (FDG) uptake in positron emission tomography (PET) was recently associated with progressive RV dysfunction in MRI, but the prognostic value of their combination has not been established. Methods: Twenty-six clinically stable patients with PAH (49.9±15.2 years) and 12 healthy subjects (control group, 44.7±13.5 years) had simultaneous PET/MRI scans. FDG uptake was quantified as mean standardised uptake value (SUV) for both left ventricle (LV) and RV. Mean follow-up time of this study was 14.2±7.3 months and the clinical end point was defined as death or clinical deterioration. Results: Median SUVRV /SUVLV ratio was 1.02 (IQR 0.42–1.21) in PAH group and 0.16 (0.13–0.25) in controls, p<0.001. In PAH group, SUVRV /SUVLV significantly correlated with RV haemodynamic deterioration. In comparison to the stable ones, 12 patients who experienced clinical end point had significantly higher baseline SUVRV /SUVLV ratio (1.21 (IQR 0.87–1.95) vs 0.53 (0.24–1.08), p=0.01) and lower RV ejection fraction (RVEF) (37.9±5.2 vs 46.8±5.7, p=0.03). Cox regression revealed that SUVRV /SUVLV ratio was significantly associated with the time to clinical end point. Kaplan-Meier analysis showed that combination of RVEF from MRI and SUVRV /SUVLV assessment may help to predict prognosis. Conclusions: Increased RV glucose uptake in PET and decreased RVEF identify patients with PAH with worse prognosis. Combining parameters from PET and MRI may help to identify patients at higher risk who potentially benefit from therapy escalation, but this hypothesis requires prospective validation.